Organization | Umraniye Education and Research Hospital

Umraniye Education and Research Hospital Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial

2014

NCT02494466

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Istanbul Umraniye Training and Research Hospital | Umraniye Education and Research Hospital

Active Ingredients

Drugs in Phase 4 Trials (6)

clavulanate (Augmentin) (1 trial)

lactobacillus reuteri (1 trial)

montelukast (singulair) (1 trial)

phenol (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

silver nitrate (1 trial)

Drugs in Phase 3 Trials (8)

acetylcysteine (mucomyst) (1 trial)

azithromycin (zithromax) (1 trial)

favipiravir (2 trials)

hydroxychloroquine (plaquenil) (2 trials)

levocarnitine (carnitor) (1 trial)

nicotinamide (1 trial)

ribavirin (virazole) (1 trial)

sorbitol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diarrhea (Phase 4)

Pilonidal Sinus (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 14